Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Primary tabs
View
(active tab)
Ignyta
January 02, 2018
Pharma news over the Christmas period
December 22, 2017
Ignyta investors have the last laugh
November 14, 2017
Loxo’s Bayer deal falls short of bullish expectations
October 19, 2017
World Lung – Spectrum shoots for another lung cancer niche
October 18, 2017
World Lung – Ignyta’s chance to make up lost ground on Loxo
October 12, 2017
Lung cancer focus – drugging the undruggable KRAS
October 11, 2017
World Lung and SITC – two more doses of oncology
July 10, 2017
Strong small cap performance drives second-quarter gains
June 08, 2017
Asco event analyser – Puma investors’ Aphinity for Roche data
June 03, 2017
Asco – Loxo nudges ahead of Ignyta with tumour-agnostic therapy
January 24, 2017
Vantage point – Life for kinase inhibitors in an immuno-oncology world
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 31, 2019
Vantage Pharma, Biotech & Medtech Half-Year Review 2019
February 26, 2019
Vantage Pharma, Biotech and Medtech 2018 in Review
Editor's Picks
September 05, 2019
Esmo 2019 preview – Parps on parade
September 10, 2019
Alzheimer's setbacks have prompted $39bn of market cap losses this year
September 12, 2019
Should the diabetes development road end for Sanofi?
August 27, 2019
Six burning Otezla questions
August 29, 2019
The PCSK9 wars continue, but at what cost?
